| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net income | -3.2 | -3.6 |
| EPS (diluted, $ a share) | $-0.18 | $-0.28 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +2005.6% |
|---|
10-Q filed with the SEC, NASDAQ: DARE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Dare Bioscience, Inc.: key numbers
- Share price
- $0.5842Close, Nov 16
- Market cap
- $11.5M
- Shares outstanding
- 19.67MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Dare Bioscience, Inc.
All →Dare Bioscience Financial Results
Insight Molecular Diagnostics (iMDx) reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center and the appointment of a new transplant sales leader to prepare for commercial launch.
- Term
- Q3 2026
Dare Bioscience Capital Raise
Stockholders of Daré Bioscience approved the potential future issuance of common stock upon the exercise of outstanding warrants in accordance with Nasdaq listing rules. The approval was obtained at a special meeting held on November 10, 2026, ensuring compliance with dilution limits for a previously initiated capital raise.
Dare Bioscience Nasdaq/NYSE Compliance Notice
Daré Bioscience received a deficiency notice from Nasdaq on September 28, 2026, because its common stock closing bid price fell below the $1.00 minimum requirement for 30 consecutive business days. The company has until March 29, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The notice has no immediate effect on the listing, and the company may be eligible for an additional 180-day compliance period if necessary.
- Counterparty
- Nasdaq
- Term
- 180 days
Dare Bioscience Investor Presentation
Daré Bioscience, Inc. filed a corporate presentation dated October 1, 2026, as an exhibit to its 8-K. The company intends to use this presentation in meetings with securities market participants and has made it available on its investor relations website.